Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a clinical-stage oncology company developing precision medicines targeting families of oncogenic mutations in patients with genetically defined cancers. The company's website is www.blackdiamondtherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Black Diamond Therapeutics, Inc. does
In the company’s own words
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a clinical-stage oncology company developing precision medicines targeting families of oncogenic mutations in patients with genetically defined cancers. The company's website is www.blackdiamondtherapeutics.com.
Founded in 2014, Black Diamond Therapeutics built its foundation on deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. The company's proprietary Mutation-Allostery-Pharmacology (MAP) drug discovery engine identifies oncogenic mutations, confirms their oncogenicity through cell and tumor models, and enables pharmacologic inhibition while sparing wild-type proteins. This approach recognizes that mutations throughout a gene can drive oncogenic activation and be grouped into families sharing similar selectivity profiles, allowing a single molecule to inhibit multiple mutations regardless of location on the receptor.
The company's lead clinical-stage program is silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor currently in Phase 2 clinical trials for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and planned for a randomized Phase 2 trial in newly diagnosed EGFR-altered glioblastoma (GBM) in the second quarter of 2026. Silevertinib has received Fast Track Designation from the FDA for treating EGFR mutant C797S-positive NSCLC. The company's pipeline also includes BDTX-4933, a brain-penetrant RAF MasterKey inhibitor licensed globally to Servier Pharmaceuticals in 2025, and BDTX-4876, a selective FGFR2/3 inhibitor for which the company is exploring partnership opportunities.
Black Diamond Therapeutics' MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and penetrate the central nervous system. The company's strategy focuses on generating Phase 2 clinical data for silevertinib to enable potential pivotal trials, conducting Phase 2 trials in GBM, and evaluating strategic partnerships to advance development and maximize pipeline value. As a smaller reporting company, Black Diamond Therapeutics operates as a clinical-stage biopharmaceutical enterprise focused on precision oncology medicine for patients with limited treatment options.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1701541
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Black Diamond Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Black Diamond Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Black Diamond Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Black Diamond Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Black Diamond Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”